A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to learn if the study drug (custirsen), when given with cabazitaxel and prednisone, is better than cabazitaxel and prednisone alone at increasing survival in patients with metastatic, castrate resistant prostate cancer. The study will also see if custirsen is safe when given with cabazitaxel and prednisone.
Metastatic Castrate Resistant Prostate Cancer
*Metastatic prostate cancer
*Previous treatment with Docetaxel
18 - 100
Healthy Volunteers Needed
Duration of Participation
Up to 7.5 months on treatment
Rachel Slottke (503) 494-6117
OncoGeneX Technologies Inc.